Latigo posts outcomes on competitor to Vertex non-opioid ache reliever

For many years, efforts to develop non-opioid ache medication had been marked by failure. However what was as soon as a graveyard of drug discovery is rapidly turning right into a race for a multibillion-dollar market, with Latigo Biotherapeutics publishing optimistic knowledge on Wednesday for a remedy meant to rival a Vertex drugs already in the marketplace.

The startup’s Part 2 trial enrolled 343 sufferers who’d gotten tummy tuck surgical procedure; they had been randomized to obtain a excessive or low dose of Latigo’s experimental tablet, a placebo, or a mix of acetaminophen and the opioid hydrocodone. These given both dose of Latigo’s oral drug, LTG-001, confirmed statistically vital ache aid in comparison with placebo after 48 hours. And whereas members in all teams had the choice to make use of the opioid oxycodone in the event that they wanted further ache administration, these on a excessive dose of Latigo’s remedy had been considerably much less probably to take action than members on placebo.

The drug was typically protected and effectively tolerated, with greater general opposed occasion charges within the placebo group than in both remedy group. Some opposed occasions, nevertheless, had been extra widespread within the remedy teams: 7% of these taking a excessive dose of LTG-001 had a fever, in contrast with 2% of individuals on placebo, and 6% skilled lightheadedness, in contrast with 1% of the placebo group.